



TMU-Research Center of Urology and Kidney Monthly Meeting

Times : 2026/08/13(Thursday) 12:00-13:30

Google meet link : <https://meet.google.com/ihn-wugo-jfv>

Meeting Chairperson : Mei-Yi Wu

Participant :

【TMUH】 Ming-Zhe Liu, Shao-De Ye, Zhi-Qi Gao, Jian-Zhi Wu, Zheng-Cheng Wu, Jing-Xin Zhang, De-Zhao Fang, Yi-Wen Wu, Xi-Xian Chen, Yang-Ren Jiang, Jing-Yi Chen, Yan-Zhong Lin, Yue-Zhu Shao, An-Qi Zhou, Zhi-Kuan Wu, Qi-Tai Li, Xiao-You Lin, Jian-Rong Huang, Zhen-Wen Chen, Bao-Bao Chen, Dong-Lin Cai

【WFH】 Yu-Qing Wen, Ming-Zhe Li, Wei-Wen Zhang, Yong-Wei Lin, Zhi-Hao Xiao, Xuan-Hao Xu, Zong-Hao Lai, Zhuo-Xing Zhong, Zhong-Yi Zheng, Zuo-Xiao Chen, Chong-De Liu, Yun-Hong Yang, Yu-Xiang Yang, Liang-Ming Li, Ke-Xun Lin, Yue-Lin Wu, Hong-Wei Liao

【SHH】 Ming-Zhe Li, Jia-Zhang Wu, Guan-Zhou Chen, Jia-Hong Liu, Yi-De Jiang, Kai-Yi Zou, Wei-Tang Gao, Shu-Wei Hu, Mei-Yi Wu, Li-Yu Hong, Cai-Mei Zheng, Jia-De Liao, Rui-Xiang Song, Min-Guang Cai, You-Wei Chen, Zhi-Hua Gao, Guan-Hong Lin, Jian-Hua Zeng, Bo-Han Qiu, Zhi-Heng Chen, Shao-Wei Dong, Yu-Cong Yin, Yu-Feng Lin

【TMU】 Wei-Cheng Luo

【SKMH】 Yu-Mou Su, Ju-Lin Zou, Ming-Jie Jiang, Yu-Chan Lin, Wen-Ling WeiChu-Lin Chou

Chief : Mai-Szu Wu (President, TMU) 、 Chih-Cheng Hsu (Professor, NHRI) 、
Ruei-Ming Chen 、 Shing-Hwa Lu 、 Yung-Ho Hsu

Agenda: :

I. Invited Speaker – Prof. Daw-Yang Hwang, Assistant Investigator / Attending Physician National Institute of Cancer Research

Topic: Applications of Genetic Testing in Nephrology

II. Administrative Announcements

1. The Center's official website is currently being redesigned by a contracted vendor. Members are welcome to provide notable achievements or highlights for inclusion on the new website. (Please email relevant materials to 26281@s.tmu.edu.tw or share them via the RCUK group.)
2. The next regular meeting will be held on September 17, 2026 (Thursday), 12:00–1:30 PM.
 - Guest Lecture: Dr. Chung-You Tsai Far Eastern Memorial Hospital to deliver a lecture at the meeting.
 - Team Presentation: Uro-Renal Cancer Team. (If presentation assistance is required, please provide the slides no later than one day prior to the meeting.)
3. We kindly ask the Chiefs of the three affiliated hospitals and three divisions to assist in inviting members who have not yet joined the LINE group to do so as soon as possible, in order to ensure timely communication of upcoming events and announcements.

(The LINE group currently has 47 members including the secretary, while RCUK has a total of 70 members.)

基因檢測在腎臟領域的運用

12:00 - 13:30

地點

衛生福利部雙和醫院
第一醫療大樓10樓第一會議室

2026

08/13

(四)



黃道揚 教授

現職：

國家衛生研究院 癌症研究所 助研究員級主治醫師
高雄醫學大學附設中和紀念醫院 主治醫師
高雄醫學大學 醫學系 助理教授





研究領域：

癌症基因體學、遺傳性疾病研究、
癌症驅動基因、轉譯醫學

國家衛生研究院
National Health Research Institute

- Prevalence: ADTKD 16/million, ADTKD-UMOD: 9/million
- Recent studies have shown that it represents up to 0.3~2% of all CKD patients.
- Genes: *UMOD*, *MUC1*, *HNF1B*, *REN*, *SEC62IA1*



- Gene panel testing from KMH Cohort
- Most have kidney biopsy performed
- N = 1,500
- Panel contains adult-NS related 21 genes
- Identified 109 variants that are associated with NS
- Estimated 7% may have genetic causes in our cohort



Year	Country	Population (millions)	Urban population (millions)	Urban population (%)	Urban population (millions)	Urban population (%)
1990	1990	1.2	0.8	66.7	0.8	66.7
2000	2000	1.5	1.0	66.7	1.0	66.7
2010	2010	1.8	1.2	66.7	1.2	66.7
2020	2020	2.1	1.5	71.4	1.5	71.4
2030	2030	2.4	1.8	75.0	1.8	75.0
2040	2040	2.7	2.1	77.8	2.1	77.8
2050	2050	3.0	2.4	80.0	2.4	80.0
2060	2060	3.3	2.7	81.8	2.7	81.8
2070	2070	3.6	3.0	83.3	3.0	83.3
2080	2080	3.9	3.3	84.6	3.3	84.6
2090	2090	4.2	3.6	85.7	3.6	85.7
2100	2100	4.5	3.9	86.7	3.9	86.7

Figure 1 consists of three pie charts labeled (a), (b), and (c), showing the distribution of variables in the dataset.

- (a) ASDI2 (Categorical):** This pie chart shows the distribution of the ASDI2 variable across 10 categories. The categories and their approximate percentages are: ASDI2 = 1 (20%), ASDI2 = 2 (20%), ASDI2 = 3 (20%), ASDI2 = 4 (20%), ASDI2 = 5 (20%), ASDI2 = 6 (10%), ASDI2 = 7 (10%), ASDI2 = 8 (10%), ASDI2 = 9 (10%), and ASDI2 = 10 (10%).
- (b) ASDI2 (Continuous):** This pie chart shows the distribution of the ASDI2 variable across 5 categories. The categories and their approximate percentages are: ASDI2 < 1 (20%), ASDI2 < 2 (20%), ASDI2 < 3 (20%), ASDI2 < 4 (20%), and ASDI2 < 5 (20%).
- (c) ASDI2 (Binary):** This pie chart shows the distribution of the ASDI2 variable across 2 categories. The categories and their approximate percentages are: ASDI2 = 0 (20%) and ASDI2 = 1 (80%).

PKD Genetic Diagnostic Category	Patients	% Cohort
Core ADPKD (PKD1/PKD2)	1702	86.7%
ADPKD-spectrum	120	6.1%
ARPKD/recessive PKD	55	2.8%
Multiple PKD-related genes	48	2.4%
Syndromic/cystic phenocopy	30	1.5%
Possible/other PKD-related	7	0.4%
Total	1962	100.0%

Cohort	n	n	Age	Age	eGFR	eGFR	GFR	GFR	Rapid	Rapid	Severe	Severe
	age ^a	stop	SD	SD	mean	SD	slope	slope	<-3.5	<-5.5	<-5.5	<-5.5
PKD1-T	149	130	44.2	12.0	57.1	42.6	-0.02	3.84	71	54.6	41	31.6
PKD1-NT	124	100	50.9	16.3	63.6	42.3	-0.15	4.95	44	44	23	23
PKD2	138	119	51.9	14.6	68.9	38.1	-0.36	3.32	41	34.6	16	13.45



SpaceOAR™ Hydrogel

A little Space Makes A Big Difference

Presenter: 賴宗憲
萬芳醫院 泌尿科

SpaceOAR™ Hydrogel Overview

Space OrganAtRisk

- 創設泌尿器影像系統
- 2022.12.18 發布可選
- 泌尿科第一間與癌症治療相關
- 第一安寧、電療在 25°C 以下
- 臺北醫學大學、陽明大學、成功大學、高雄醫學大學、長庚大學、慈濟大學、中興大學、逢甲大學、嘉祥大學、弘光大學、勤益科技大學、大同大學、銘傳大學、長庚大學、慈濟大學、中興大學、逢甲大學、嘉祥大學、弘光大學、勤益科技大學、大同大學、銘傳大學

What is SpaceOAR™ Hydrogel?

Rectum and Prostate Movement

Prostate Description

Prostate-rectum Spacing

Device Preparation & Kit Assembly

Two Primary Study Flows^{2,3}

Initial Procedure Results²

Parameter	Post-Procedure	12 weeks	12 months
Prostate Size	10.0 ± 2.5 cm	10.0 ± 2.5 cm	10.0 ± 2.5 cm
Rectum Size	10.0 ± 2.5 cm	10.0 ± 2.5 cm	10.0 ± 2.5 cm

Study Results

Bowel Study Results^{3,5}

Bowel Study Results³

Bowel Study Results³

Required Equipment

How is SpaceOAR™ Hydrogel Placed?

SpaceOAR™ Hydrogel Clinical Data

SpaceOAR™ Hydrogel Clinical Data

SpaceOAR™ Hydrogel Clinical Trial

Study Design^{2,3}

Urinary Study Results³

Sexual Study Results⁴

Study Results – Patient Quality of Life³

Clinical Evidence Summary

References

Thank you for your attention